Reported 2 days ago
H.C. Wainwright has updated its price target for Ocular Therapeutix Inc. (NASDAQ:OCUL) from $15 to $19 while maintaining a Buy rating. This adjustment follows the FDA granting Special Protocol Assessment for AXPAXLI, intended for treating non-proliferative diabetic retinopathy. Ocular Therapeutix is involved in developing therapies for eye-related conditions and has presented trials HELIOS-2 and HELIOS-3, showcasing the potential of its product pipeline.
Source: YAHOO